Literature DB >> 18322950

Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.

Kenichi Hakamada1, Norihisa Kimura, Takuya Miura, Hajime Morohashi, Keinosuke Ishido, Masaki Nara, Yoshikazu Toyoki, Shunji Narumi, Mutsuo Sasaki.   

Abstract

AIM: To clarify the effect of a high des-gamma-carboxy prothrombin (DCP) level on the invasiveness and prognosis of small hepatocellular carcinoma.
METHODS: Among 142 consecutive patients with known DCP levels, who underwent hepatectomy because of hepatocellular carcinoma, 85 patients met the criteria for small hepatocellular carcinoma, i.e. one<or=5 cm sized single tumor or no more than three<or=3 cm sized tumors.
RESULTS: The overall survival rate of the 142 patients was 92.1% for 1 year, 69.6% for 3 years, and 56.9% for 5 years. Multivariate analysis showed that microscopic vascular invasion (P=0.03) and serum DCP>or=400 mAU/mL (P=0.02) were independent prognostic factors. In the group of patients who met the criteria for small hepatocellular carcinoma, DCP>or=400 mAU/mL was found to be an independent prognostic factor for recurrence-free (P=0.02) and overall survival (P=0.0005). In patients who did not meet the criteria, the presence of vascular invasion was an independent factor for recurrence-free (P=0.02) and overall survivals (P=0.01). In 75% of patients with small hepatocellular carcinoma and high DCP levels, recurrence occurred extrahepatically.
CONCLUSION: For small hepatocellular carcinoma, a high preoperative DCP level appears indicative for tumor recurrence. Because many patients with a high preoperative DCP level develop extrahepatic recurrence, it is necessary to screen the whole body.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322950      PMCID: PMC2693684          DOI: 10.3748/wjg.14.1370

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.

Authors:  G L Grazi; A Mazziotti; C Legnani; E Jovine; R Miniero; A Gallucci; G Palareti; G Gozzetti
Journal:  Liver Transpl Surg       Date:  1995-07

2.  Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.

Authors:  Mayumi Suzuki; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Naoki Ueda; Yutaka Nakanishi; Kazuko Koike; Akinobu Takaki; Yasushi Shiratori
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

Review 3.  Living-donor liver transplantation for hepatocellular carcinoma.

Authors:  Hiroyuki Furukawa; Tsuyoshi Shimamura; Tomomi Suzuki; Masahiko Taniguchi; Kenichiro Yamashita; Toshiya Kamiyama; Michiaki Matsushita; Satoru Todo
Journal:  J Hepatobiliary Pancreat Surg       Date:  2006

4.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

5.  gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.

Authors:  Toru Naraki; Noriatsu Kohno; Hiroyuki Saito; Yoshinori Fujimoto; Motoyuki Ohhira; Takashi Morita; Yutaka Kohgo
Journal:  Biochim Biophys Acta       Date:  2002-04-24

6.  Clinicopathological characteristics of patients with extrahepatic recurrence following a hepatectomy for hepatocellular carcinoma.

Authors:  T Utsunomiya; M Shimada; K Shirabe; K Kajiyama; T Gion; K Takenaka; K Sugimachi
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

7.  The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

Authors:  Ken Shirabe; Shinji Itoh; Tomoharu Yoshizumi; Yuji Soejima; Akinobu Taketomi; Shin-Ichi Aishima; Yoshihiko Maehara
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

8.  Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.

Authors:  Hidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Fumihiro Urano; Masatoshi Kudo; Takashi Matsunaga
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

9.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation.

Authors:  Motoyuki Otsuka; Naoya Kato; Run-Xuan Shao; Yujin Hoshida; Hideaki Ijichi; Yukihiro Koike; Hiroyoshi Taniguchi; Masaru Moriyama; Yasushi Shiratori; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.

Authors:  Masaki Kaibori; Yoichi Matsui; Hidesuke Yanagida; Norio Yokoigawa; A-Hon Kwon; Yasuo Kamiyama
Journal:  World J Surg       Date:  2004-06-08       Impact factor: 3.352

View more
  11 in total

1.  Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.

Authors:  Mohammed Elshamy; Federico Aucejo; K V Narayanan Menon; Bijan Eghtesad
Journal:  World J Hepatol       Date:  2016-07-28

2.  Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.

Authors:  Yasunari Hiramine; Hirofumi Uto; Yasushi Imamura; Kazuaki Tabu; Yoshirou Baba; Takuya Hiwaki; Yukihiko Sho; Kenji Tahara; Hirofumi Higashi; Tutomu Tamai; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

Review 3.  Downstaging for hepatocellular cancer: harm or benefit?

Authors:  Kathleen Bryce; Emmanuel A Tsochatzis
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-12

4.  Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation.

Authors:  Seok-Hwan Kim; Deok-Bog Moon; Wan-Joon Kim; Woo-Hyoung Kang; Jae Hyun Kwon; Eun Kyung Jwa; Hwui-Dong Cho; Su-Min Ha; Yong-Kyu Chung; Sung-Gyu Lee
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

5.  Expression and characterization of recombinant ecarin.

Authors:  Anna Jonebring; Ute Lange; Elke Bucha; Johanna Deinum; Margareta Elg; Ann Lövgren
Journal:  Protein J       Date:  2012-06       Impact factor: 2.371

Review 6.  Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.

Authors:  C G Cristea; I A Gheonea; L D Săndulescu; D I Gheonea; T Ciurea; M R Purcarea
Journal:  J Med Life       Date:  2015 Apr-Jun

7.  PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.

Authors:  Carlo Saitta; Giuseppina Raffa; Angela Alibrandi; Santa Brancatelli; Daniele Lombardo; Gianluca Tripodi; Giovanni Raimondo; Teresa Pollicino
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

8.  Recombinant snake venom prothrombin activators.

Authors:  Ann Lövgren
Journal:  Bioengineered       Date:  2012-10-30       Impact factor: 3.269

9.  Transcatheter arterial chemoembolization: history for more than 30 years.

Authors:  Yong-Song Guan; Qing He; Ming-Quan Wang
Journal:  ISRN Gastroenterol       Date:  2012-08-26

10.  Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas.

Authors:  Yanyan Wei; Feng Dai; Yongxiang Yi; Wei Ye; Wei Zhao
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.